



Short profile

Coronis Neuroscience Ltd.

CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)

Medical field	Neuroscience, Primary Care
Product (name and type)	CP202, Biopharmaceuticals
Growth stage	Proof of Concept
Founders	Eric J. Messika (President, CEO, Founder)

Description of product:

CP202 Active Pharmaceutical Ingredient(API) is an 8 amino acid active site of ADNP (1102 amino acids) dedicated to orphan drug markets. CP202a subcutaneous needle free injection formulation. The API crosses the blood brain barrier and enter cells by endocytosis. Binding to microtubules (the crucial cell skeleton and transport system) it fortifies ADNP's activity, restores and enhances nerve cell plasticity. It also protects the immune synapse against enhanced inflammatory response. The product is initially intended for the ADNP syndrome, and is further envisioned to be tested and verified in multiple-related orphan autism spectrum disorders (ASDs), based on a portfolio of preclinical studies. Further future uses include inflammatory indications.



Eligible by the IIA



eric@coronisns.com



Eric Messika: 0544257382



<http://www.coronisns.com/>

Project goal:

1. Discovery of new route of administration, needle free, children friendly SC administration mode, including safety, pharmacokinetics and dose finding
2. Discovery/characterization of objective exploratory biomarkers including visual and auditory evoked potential, microbiome/immune profiles and actometry.

Project type:

Clinical Trial, Study Phase I/II. Estimated duration: 12 months

